ArticleCancer discovery2021
Oncogenic
Abstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Targeting p53 pathways: mechanisms, structures, and advances in therapy.Signal transduction and targeted therapy · 2023Pooled it
- Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.Nature medicine · 2026Trial
- MVB Maturation Responsive to KRASJournal of extracellular vesicles · 2026Article
- From Oncolysis to Adaptive Immunity: Yellow Fever Virus 17D and Ruxolitinib Activate Antitumor Immune Responses in Pancreatic Cancer Models.Biomedicines · 2026Article
- The AUTACE That Degrades KRAS and Engages CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Dual-layer spectral detector CT: a non-invasive tool for simultaneously predicting Ki-67 proliferation status and p53 mutations in pancreatic ductal adenocarcinoma.Abdominal radiology (New York) · 2026Article
- Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- A 5-marker immunohistochemical panel of CK17, MEP1A, PAX8, SMAD4, and CDX2 to distinguish ovarian mucinous carcinoma from metastatic pancreatic ductal adenocarcinoma.Histopathology · 2026Article
- CREB Fuels Tumorigenesis in Alcoholic Pancreatitis.Cellular and molecular gastroenterology and hepatology · 2026Article
- Loss of FAT1 drives cyclophosphamide resistance in breast cancer via the Wnt/β-Catenin pathway.International journal of biological sciences · 2026Article
- Stromal fibroblastic mutant Trp53 promotes mammary tumor development via enhanced secretion of paracrine factors.NPJ breast cancer · 2025Article
- Targeting Mast Cell Activation and MIF-Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Clinical and Molecular Characteristics ofInternational journal of molecular sciences · 2025Article
- Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency.Cancer cell · 2025Article
- PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with aFuture oncology (London, England) · 2025Article
- Coexistence of P53 and KRAS mutations enhances ERK1/2 signaling by inducing EGR1 expression through mutp53 and c-JUN interaction.Oncogene · 2025Article
- Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis.NPJ precision oncology · 2025Article
- Targeting macrophage migration inhibitory factor as a potential therapeutic strategy in colorectal cancer.Oncogenesis · 2025Article
- Pathway-Specific Genomic Alterations in Pancreatic Cancer Across Populations at Risk.International journal of molecular sciences · 2025Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Michael P KimDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. mkim@mdanderson.org gglozano@mdanderson.org.
Xinqun LiDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jenying DengDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yun ZhangDepartment of Pharmaceutical Sciences, Texas Southern University, Houston, Texas.
Bingbing DaiDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kendra L AlltonDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Tara G HughesDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Christian SiangcoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jithesh J AugustineDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ya'an KangDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2076-3692
Joy M McDanielDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5767-6904
Shunbin XiongDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Eugene J KoayDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7675-3461
Florencia McAllisterDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Christopher A BristowInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Timothy P HeffernanInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3166-8922
Anirban MaitraSheikh Ahmed Pancreatic Cancer Research Center, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bin LiuDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9113-9694
Michelle C BartonDivision of Oncological Sciences, Oregon Health and Science University School of Medicine, Portland, Oregon.ORCID 0000-0002-4042-1374
Amanda R WasylishenDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1940-5169
Jason B FlemingDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Guillermina LozanoDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas. mkim@mdanderson.org gglozano@mdanderson.org.ORCID 0000-0001-8985-4886
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MThe RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7MTRAINING OF ACADEMIC SURGICAL ONCOLOGISTST32CA009599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Ashley M Holder, Jennifer A. Wargo · 1988 to 2026
$13.2MRole of p53 Missense Mutations on Tumorigenesis in VivoR01CA082577 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOZANO, GUILLERMINA · 1999 to 2024
$7.3MDefining diverse roles of p53 in pancreatic cancerK08CA218690 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KIM, MICHAEL PAUL · 2017 to 2021
$853kThe Age-Dependence and Cell-Specificity of Breast Cancer Driven by Mutant p53SC2GM135111 · NIGMS · TEXAS SOUTHERN UNIVERSITY · PI ZHANG, YUN · 2020 to 2022
$459kUpgrading an existing NIKON A1-confocal with LUNV Laser Launch and DU-G detectorS10OD024976 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOZANO, GUILLERMINA · 2018 to 2018
$202kNCI NIH HHS K08 CA218690NCI NIH HHS P01 CA117969NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA082577NCI NIH HHS T32 CA009599NIGMS NIH HHS SC2 GM135111NIH HHS S10 OD024976
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is almost uniformly fatal and characterized by early metastasis. Oncogenic
Indexed as
AnimalsCarcinoma, Pancreatic DuctalFemaleGene Regulatory NetworksGenes, p53HumansMiceMice, Inbred C57BLMice, NudeNeoplasm MetastasisPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.